Filing Flows › Xenon Pharmaceuticals (XENE) › Q1 2025
Xenon Pharmaceuticals (XENE) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Xenon Pharmaceuticals (XENE) reported revenue of $7.5M for the first quarter 2025 (Q1 2025). Operating margin was -969.8%, net loss $65.0M (867.3% of revenue).
Xenon Pharmaceuticals, Q1 2025: revenue $7.5M, operating margin -969.8%, net loss $65.0M, operating cash flow −$61.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.5M | — | — |
| Operating profit | −$72.7M | — | — |
| Net earnings | −$65.0M | — | — |
| Operating cash flow | −$61.7M | — | — |
What changed
Revenue was $7.5M in Q1 2025.
Operating costs exceeded revenue by $72.7M, an operating margin of -969.8%. The quarter ended with a net loss of $65.0M.
Operating cash flow was −$61.7M. Non-cash charges added back $659K of depreciation and amortization and $12.2M of share-based compensation. Working capital and other items used $9.4M. Capital expenditures of $43K exceeded it, leaving free cash flow of −$61.7M.
Questions
What was Xenon Pharmaceuticals' revenue in the first quarter 2025?
Xenon Pharmaceuticals (XENE) reported revenue of $7.5M for the first quarter 2025 (Q1 2025).
Was Xenon Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $72.7M (-969.8% of revenue) and net loss $65.0M.